Jpmorgan Chase & CO Biovie Inc. Transaction History

Jpmorgan Chase & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Dec 26, 2024	BUY	$0.4 - $0.56 $5,068 - $7,096	12,672 New	12,672 $5,000
Q2 2024 Aug 12, 2024	BUY	$0.4 - $0.56 $4,092 - $5,728	10,230 Added 418.92%	12,672 $5,000
Q1 2024 Dec 26, 2024	BUY	$0.53 - $1.89 $1,294 - $4,615	2,442 New	2,442 $1,000
Q1 2024 May 10, 2024	BUY	$0.53 - $1.89 $148 - $529	280 Added 12.95%	2,442 $1,000
Q4 2023 Dec 26, 2024	BUY	$1.22 - $5.24 $2,637 - $11,328	2,162 New	2,162 $2,000
Q4 2023 Feb 12, 2024	BUY	$1.22 - $5.24 $12 - $52	10 Added 0.46%	2,162 $2,000
Q3 2023 Nov 14, 2023	SELL	$2.75 - $5.17 $1,358 - $2,553	-494 Reduced 18.67%	2,152 $7,000
Q2 2023 Aug 11, 2023	BUY	$4.09 - $8.29 $10,822 - $21,935	2,646 New	2,646 $11,000

340K

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $68.5M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.